Skip to main content
. 2025 Aug 26;11(4):00969-2024. doi: 10.1183/23120541.00969-2024

FIGURE 2.

FIGURE 2

Area under the curve (AUC) and 95% confidence interval of the models predicting each response outcome. Datasets: overall data, anti-interleukin (IL)-5/IL-5Rα users and anti-IL-4Rα users. Model 1 (M1): outcome—BEC+covariates; Model 2 (M2): outcome—Sp-EOS+covariates; Model 3 (M3): outcome—FENO+covariates; Model 4 (M4): outcome—BEC+Sp-EOS+covariates; Model 5 (M5): outcome—BEC+FENO+covariates; Model 6 (M6): outcome—FENO+Sp-EOS+covariates; Model 7 (M7): outcome—BEC+Sp-EOS+FENO+covariates. Covariates were age and sex. Data are presented as the mean and 95% confidence intervals of the AUC of the receiver operating characteristic (ROC) curves. The vertical dashed grey line is the reference line for the AUC value of 0.5. Pairwise comparisons of AUC by DeLong test with p-value <0.05: a: M1 versus M2; b: M1 versus M3; c: M1 versus M4; d: M1 versus M5; e: M1 versus M6; f: M1 versus M7; g: M2 versus M3; h: M2 versus M4; i: M2 versus M5; j: M2 versus M6; k: M2 versus M7; l: M3 versus M4; m: M3 versus M5; n: M3 versus M6; o: M3 versus M7; p: M4 versus M5; q: M4 versus M6; r: M4 versus M7; s: M5 versus M6; t: M5 versus M7; u: M6 versus M7. EXA-OCS-Res: responder is defined as a reduction by ≥50% in the annual exacerbation rate, or a reduction by ≥50% in the maintenance oral corticosteroid (mOCS) dose, or remaining without exacerbations; FEV1-Res: FEV1 responder is defined as having a 12-month visit FEV1 ≥80%, or an FEV1 increase by ≥100 mL and ≥10%; ACT-Res: ACT responder is defined as having a 12-month visit ACT score ≥20, or an ACT score increase by ≥3 points; Clin-Rem: clinical remission is defined as having no mOCS use and no exacerbations during the 12-month follow-up, plus meeting the criteria for FEV1-Res and ACT-Res. BEC: blood eosinophil count; Sp-EOS: sputum eosinophils; FENO: fractional exhaled nitric oxide.